U.S. FDA APPROVES EISAI’S DAYVIGO™ (LEMBOREXANT) FOR TREATMENT OF INSOMNIA IN ADULT PATIENTSOREXIN RECEPTOR ANTAGONIST PROVEN EFFECTIVE FOR BOTH SLEEP ONSET AND SLEEP MAINTENANCE IN CLINICAL DEVELOPMENT PROGRAM